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Abstract Triclabendazole is the current drug of choice
against Fasciola spp. infections in livestock, but resistance
has become a major problem. In this study, we assessed the
efficacy and safety of artemether, a derivative of artemisi-
nin, in sheep with a low natural Fasciola hepatica
infection. Artemether was administered orally or intramus-
cularly; sheep were monitored for 8 h posttreatment and
then once daily for adverse events, and drug efficacy was
estimated by fecal egg count reductions and worm burden
reductions. Single 40- and 80-mg/kg oral doses of
artemether showed no effect on F. hepatica egg and worm
burden. Treatment with a single 160-mg/kg intramuscular
dose of artemether significantly reduced the egg burden
(64.9%) and worm burden (91.3%). At half this dose, a
worm burden reduction of 65.3% was obtained, which was
still statistically significant (P<0.05). The lowest intramus-
cular dose of artemether investigated (40 mg/kg) yielded no
effect on egg counts and worm burden. There were no
adverse events due to artemether; however, two abortions
were observed 7 days posttreatment. In conclusion, arte-
mether shows interesting fasciocidal properties in sheep,
but embryotoxicity is of concern. Further studies are
warranted to assess the potential of additional artemisinin
derivatives and other peroxidic compounds for the treat-
ment of Fasciola spp. infections in different ruminants.
Introduction
Fascioliasis (fasciolosis), caused by liver flukes of the species
Fasciola hepatica and F. gigantica, is a significant livestock
and an emerging public health problem (McManus and
Dalton 2006; Keiser and Utzinger 2007). An estimated 350
million cattle, 250 million sheep, and 91 million people are
at risk of acquiring an infection from Fasciola spp. (Keiser
and Utzinger 2007; Rioux et al. 2007). The annual economic
loss due to fascioliasis in the veterinary field has been
estimated at US$ 2–3 billion, as a result of animal weight
loss, reduction of milk yield and fertility declines (Schweizer
et al. 2005; McManus and Dalton 2006; Rioux et al. 2007).
The control of fascioliasis is crucial for the health, and
hence productivity of farm animals, most notably cattle and
sheep. As there is presently no vaccine available for the
prevention of fascioliasis (McManus and Dalton 2006)
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effective control rests on chemotherapy. Triclabendazole is
the current drug of choice. It is safe and efficacious against
both juvenile and adult flukes. Other veterinary fascioli-
cides (e.g. clorsulon, albendazole, rafoxanide, and closan-
tel) lack activity against the young migrating F. hepatica
stages, which cause extensive hemorrhaging and fibrosis of
the liver (Fairweather and Boray 1999). However, tricla-
bendazole resistance has been developed and is spreading;
indeed, resistance has been reported in livestock farms
across Europe (Ireland, The Netherlands, Spain, and the
UK) and in Australia (Keiser et al. 2005; Alvarez-Sanchez
et al. 2006). In addition, triclabendazole has a number of
shortcomings. First, the drug has a relatively long with-
holding period, i.e., 28 days before slaughtering animals
and 7 days before milking for human consumption (http://
www.ah.novartis.com). Triclabendazole is therefore not an
ideal drug for use in dairy sheep. Second, no injectable
formulation of triclabendazole is currently available. Third,
triclabendazole is presently not marketed in all Fasciola-
endemic countries. In Italy, for example, triclabendazole is
not readily available (Cringoli 2006).
The development of novel fasciocidal drugs that are
effective against juvenile and adult stages of Fasciola spp.
and triclabendazole-resistant Fasciola strains would be a
major advance. We have recently reported fasciocidal
properties of artemether and artesunate (derivatives of
artemisinin), which are best known for their antimalarial
(Davis et al. 2005) and antischistosomal properties
(Utzinger et al. 2007). Administration of single-dose oral
artemether (200 mg/kg) and artesunate (400 mg/kg) to rats
infected with adult F. hepatica resulted in 100% worm
burden reductions (Keiser et al. 2006a). Moreover, single-
dose oral artemether and artesunate (200 mg/kg) achieved
worm burden reductions of 82% and 46%, respectively, in
rats with a 3-week immature F. hepatica infection (Keiser
et al. 2006a).
In light of the promising fasciocidal activities of the
artemisinins in the rat model, particularly artemether, we
were motivated to assess the efficacy and safety of
artemether in sheep naturally infected with F. hepatica. In
the current proof-of-concept study, we administered single
doses of artemether at different concentrations and routes of
administration, and monitored adverse events, and drug
efficacy by means of egg and worm burden reductions.
Material and methods
Study animals and ethical clearance
The study was carried out on a dairy sheep farm in the
Salerno province of southern Italy (geographical coordi-
nates: 40°33′30″ N latitude and 15°04′17″ E longitude).
Details of the study area have been described elsewhere
(Cringoli 2006). The flock contains approximately 700mixed
breed dairy sheep, which are raised and pastured on the farm
all year long. The study animals were separated from the rest
of the flock and maintained on designated pasture for the
current study.
The study was approved by the institutional review
board of the Swiss Tropical Institute (Basel, Switzerland).
Ethical clearance was granted by the Centre for Veterinary
Service of the University of Naples Federico II, which is
the central ethical committee for the control of animal
diseases and the conduct of clinical trials in this part of Italy
(Ref. no. 116/07).
Drug and solvents
Artemether was kindly provided by Dafra Pharma (Turnhout,
Belgium) and Kunming Pharmaceutical Cooperation (Kunm-
ing, People’s Republic of China). For the oral drench, a
homogeneous suspension of 7% Tween-80 and 3% ethanol
was prepared shortly before oral administration. Artemether
was dissolved in 10–30 ml peanut oil purchased from Roth
(Basel, Switzerland) for the intramuscular application.
Study design, parasitological examination, treatment,
and safety assessment
In May 2007, we collected stool samples from 100 randomly
selected sheep on the above-mentioned farm. The samples
were subjected to the FLOTAC method, which allows an
analytic sensitivity of one egg per gram of stool (EPG). The
flotation solution employed was zinc sulfate plus potassium
iodomercurate (specific density 1.45) (Cringoli et al. 2004).
The FLOTAC technique is a novel multivalent fecal egg
count method, facilitated by the FLOTAC apparatus, which
is designed to carry out flotation in a centrifuge, followed
by a transversal cut (i.e., translation) of the apical portion of
the floating suspension (Cringoli 2006).
All F. hepatica-positive sheep were included in the
study. Four additional stool samples were collected from
these sheep over consecutive days and egg counts deter-
mined as before. For each sheep, the geometric mean egg
count was determined based on the five stool examinations.
Sheep were randomly allocated to five treatment groups
and one control group, in blocks of five to seven, according
to weight and the geometric mean egg count. Animals in
group 1 (n=7) remained untreated, serving as control.
Groups 2 and 3 (n=6 sheep each) were treated orally with
single-dose artemether at 40 and 80 mg/kg, respectively.
Groups 4–6 (n=5 sheep each) received single 40, 80, and
160 mg/kg intramuscular doses of artemether, respectively.
Sheep were monitored for the occurrence of adverse events
for 8 h and then once daily posttreatment. Between days 10
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and 27 post-treatment, three to four stool samples were
collected from each sheep on consecutive days for
examination of the F. hepatica egg burden.
All sheep were slaughtered after the final stool collec-
tion. Livers were removed and transferred to the laboratory
in thermal containers. All F. hepatica flukes were harvested
from the gall bladder, liver and excised bile ducts, counted,
and recorded separately. The morphology and movement of
flukes were monitored. All procedures followed the guide-
lines of the World Association for the Advancement of
Veterinary Parasitology (WAAVP) for evaluation of the
efficacy of anthelminthic drugs in ruminants (Wood et al.
1995).
Statistical analysis
Statistical analyses were done with version 2.4.5 of
Statsdirect statistical software (Statsdirect Ltd; Cheshire,
UK). The fasciocidal effect of artemether was estimated by
analyzing the reduction of the geometric mean of fecal egg
counts pretreatment with that posttreatment. Analyses of
EPG values were performed on logarithmically transformed
log [count+1] data. The pretreatment and posttreatment
differences were analyzed by using an unpaired two-tailed
Student’s t-test, allowing for unequal variance. Data were
considered significant with a significance level of 0.05.
The responses between the medians of the treatment and
control groups regarding F. hepatica in the liver and bile
ducts were analyzed with the Kruskal–Wallis test. Differ-
ences in medians were considered to be significant at a
significance level of 0.05.
Results
Safety evaluation
There were neither physical nor clinical signs of toxicity in
sheep treated orally or intramuscularly with artemether within
8 h after treatment. Local injection site reactions were not
observed. However, two out of the 27 treated sheep, one in the
low (40mg/kg) and one in the high (160mg/kg) intramuscular
treatment group, aborted 7 days posttreatment.
Effect of artemether on F. hepatica fecal egg count
Table 1 shows the effect of artemether treatment on
F. hepatica egg counts in stool samples. Prior to artemether
administration, sheep passed between 1 and 72 EPG. At
doses of 40–80 mg/kg artemether, administered either
orally or intramuscularly, we found no or only a low and
statistically non-significant reduction of F. hepatica egg
counts (0–39%). At the highest intramuscular route of
administration (i.e., 160 mg/kg), we noted a significant egg
count reduction (64.9%; P<0.001).
Effect of artemether on F. hepatica worm burden
Table 2 summarizes the effect of oral and intramuscular
artemether on F. hepatica in terms of worm burden
reduction after dissection of sheep. We observed low worm
burden reductions of 17.4% and 39.2% after administration
of single 40- and 80-mg/kg oral doses of artemether,
respectively, with no statistical significance (KW=2.13;
P=0.354). A single 160-mg/kg intramuscular dose of
artemether resulted in a high worm burden reduction of
91.3%. At half this dose, using the same route of ad-
ministration, a worm burden reduction of 65.3% was found,
which still showed statistical significance. At the lowest
intramuscular dose investigated (40 mg/kg), there was no
apparent effect on the F. hepatica worm burden. There was
a significant difference between the number of F. hepatica
(KW=13.76; P=0.003) recovered from the intramuscularly
treated and non-treated control sheep.
No morphological alterations were detected among
F. hepatica, and the worm motor activity was similar
among F. hepatica recovered from treated compared to non-
treated sheep.
Table 1 Effect of single-dose oral and intramuscular artemether on F. hepatica fecal egg counts in sheep, expressed as geometric mean and range
of eggs per gram of stool (EPG)
Treatment
group
Dose
(mg/kg)
Route of
administration
Number of
animals
Pretreatment
geometric mean (EPG)
Range Posttreatment
geometric mean (EPG)
Range %
reduction
1 (Control) – – 7 11.3 1–72 16.3 6–48 –
2 40 Oral 6 15.8 6–48 9.6 0–60 39.0
3 80 Oral 6 12.4 1–42 15.0 6–72 0
4 40 Intramuscular 5 5.0 2–22 14.7 6–74 0
5 80 Intramuscular 5 6.3 1–30 4.7 0–36 24.2
6 160 Intramuscular 5 6.5 2–20 2.3 0–14 64.9*
Student’s t-test comparing treatment groups 2–6 to control; *P<0.001
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Discussion
We have recently reported that the two semi-synthetic
artemisinin derivatives, artemether and artesunate, exhibit
interesting activity against F. hepatica harbored in the rat
(Keiser et al. 2006a). In addition, a recent clinical study in
Vietnam has shown that artesunate might also play a role in
the treatment of acute human fascioliasis (Hien et al. 2008).
In view of our findings in the F. hepatica-rat model, we
were motivated to investigate whether the artemisinins also
exhibit fasciocidal properties in a larger animal. In the
current proof-of-concept study, we have chosen artemether,
as it is better tolerated by rats than artesunate (Keiser et al.
2006a). While artesunate has been administered to cows
aiming to elucidate pharmacokinetic and metabolism
properties of this compound (Huo et al. 1991), to our
knowledge, this is the first report on the administration of
artemether to a small ruminant. We found that single-dose
intramuscular artemether (160 mg/kg) was efficacious
against a low natural F. hepatica infection in sheep. At this
high dose, we found a worm burden reduction of 91.3%. At
half this dose, we still found a relatively high worm burden
reduction of 65.3%. However, it should be noted that, based
on egg counts, sheep harboring a low F. hepatica infection
were overrepresented in these two treatment groups.
It is interesting to note that the effect of artemether on
Fasciola egg counts in fecal samples was somewhat less
prominent. Only the highest dose of artemether, adminis-
tered intramuscularly, achieved a significant egg count
reduction (64.9%; P<0.001). Single-dose intramuscular
artemether (80 mg/kg) resulted in an egg count reduction
of only 24.2% (P>0.05). Although a positive correlation
between Fasciola worm burden and egg output has been
described (Molina et al. 2005), this association might be
less significant in low infection intensities. Nonetheless, the
fecal egg count reduction test still is the most commonly
applied technique to determine the effect of anthelminthic
drugs. WAAVP guidelines advise to use the controlled
slaughter test, as it represents the most reliable method for
evaluating anthelminthic activity in ruminants (Wood et al.
1995).
Our study revealed that single-dose oral artemether at
dosages of 40 and 80 mg/kg lacked activity against
F. hepatica in sheep. In patients suffering from acute malaria,
unfavorable pharmacokinetic parameters of intramuscular
artemether (2 mg/kg) were found compared to single-dose
oral artemether (2 mg/kg). For example, intramuscular
artemether was characterized by a considerable delay of
maximum plasma concentrations (Cmax), a threefold lower
bioavailability of antimalarial activity and a threefold lower
area under the plasma concentration–time curve (AUC)
when compared to oral artemether (Silamut et al. 2003). In
ruminants, however, the bioavailability after oral adminis-
tration of artemether might be much lower compared to
humans as this parameter is closely related to the digestive
physiology of the rumen. For example, the microflora of
the rumen, characterized by a large number of anaerobic
bacteria and protozoa is well-known to inactivate drugs.
The rumen furthermore prolongs the absorption period, and
hence residence time of the drugs (Vandamme and Ellis
2004; Formentini et al. 2005). This characteristic is a
likely explanation why the AUC of oral albendazole
sulfoxide was found to be almost fourfold lower compared
to subcutaneous administration of the same compound
(Formentini et al. 2005). Studies are ongoing in our
laboratories to elucidate the pharmacokinetic parameters
after oral administration of artemether in rats and sheep. If
the sheep studies confirm a substantial first pass metabolism
of artemether, ruminal drug delivery systems (Vandamme
and Ellis 2004) might be considered.
Artemether, even at the highest dose of 160 mg/kg
administered intramuscularly, was well tolerated by sheep.
However, an abortion was noted in two sheep 7 days
following a single 40- and 160-mg/kg intramuscular dose of
artemether. Several studies, which evaluated the safety of
the artemisinins in pregnant malaria patients, found that
birth outcomes did not differ significantly to community
rates for abortion, stillbirth, or congenital abnormality
(McGready et al. 2001; Adam et al. 2004; Clark et al.
2004). For example, the overall abortion rate for women
treated with artemisinins in Thailand during the first
trimester was 18.9% compared to an overall community
Table 2 Effect of single-dose oral and intramuscular artemether on F. hepatica worm burden reductions
Treatment group Dose (mg/kg) Route of administration Mean worm burden (SD) Total worm burden
reduction (%)
KW P
1 (Control) – – 4.6 (2.6) – –
2 40 Oral 3.8 (2.7) 17.4
3 80 Oral 2.8 (3.1) 39.2 2.13 0.354
4 40 Intramuscular 5.8 (4.6) 0
5 80 Intramuscular 1.6 (0.9) 65.3
6 160 Intramuscular 0.4 (0.9) 91.3 13.76 0.003
KW Kruskal Wallis test, SD standard deviation
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rate of 12.3% (McGready et al. 2001). However, the total
number of women pregnant in the first trimester and
exposed to an artemisinin derivative analyzed to date is
not sufficiently large for issuing a final recommendation
regarding administration of these drugs during the first
trimester of pregnancy (Clark et al. 2004). On the other
hand, embryotoxicity has been observed in laboratory
animals following high multiple doses with the artemisinins
(Chen et al. 1984; Clark et al. 2004). Hence, we currently
cannot rule out that artemether is toxic to sheep embryos,
particularly when administered at high doses as in the
present proof-of-concept study. In addition, intramuscular
administration of high doses of artemether has been
shown to produce selective damage to the brain stem
center in rodents, but only when multiple high doses of
the drug were administered. For example, intramuscular
artemether (50–100 mg/kg/day for 28 days) caused dose-
dependent neuropathologic damage to the brain stem of
mice (Nontprasert et al. 2002).
In conclusion, we have presented the first evidence that
an artemisinin derivative possesses fasciocidal properties in
small ruminants. Our results call for additional studies with
other peroxidic drugs in F. hepatica-infected sheep, ideally
in experimental infections characterized by high infection
intensities. Due to the problematic biopharmaceutical (e.g.,
solubility) and pharmacokinetic parameters of artemether,
we suggest that future work should concentrate on artesu-
nate or the synthetic 1,2,4 trioxolanes (OZ) (Vennerstrom
et al. 2004). As we have recently shown that OZ78 is highly
efficacious in rats harboring F. hepatica infections and is
well tolerated (Keiser et al. 2006b), further studies with
OZ78 in F. hepatica-infected sheep are warranted.
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